Performance characteristics of screening strategies for lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing

Cancer

Volumn 120, Issue 24, 2014, Pages 3932-3939

  Ferguson, Sarah E ^a   Aronson, Melyssa ^b   Pollett, Aaron ^a   Eiriksson, Lua R ^c   Oza, Amit M ^a   Gallinger, Steven ^b,d   Lerner Ellis, Jordan ^a   Alvandi, Zahra ^a   Bernardini, Marcus Q ^a   MacKay, Helen J ^a   Mojtahedi, Golnessa ^a   Tone, Alicia A ^a   Massey, Christine ^d   Clarke, Blaise A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Endometrial cancer; Germline mutation testing; Immunohistochemistry; Lynch syndrome; Mismatch repair

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER SCREENING; CANCER STAGING; COHORT ANALYSIS; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; FAMILY HISTORY; FEMALE; FOLLOW UP; GERMLINE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MISMATCH REPAIR; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; STRATEGIC PLANNING; WOMEN'S HEALTH; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COMPLICATION; EARLY DIAGNOSIS; ENDOMETRIAL NEOPLASMS; EVALUATION STUDY; GENETIC SCREENING; GENETICS; MIDDLE AGED; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MUTATIONAL ANALYSIS; EARLY DETECTION OF CANCER; ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC TESTING; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS;

EID: 84919333895     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28933     Document Type: Article

References (32)

1. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet. 2009; 76: 1-18.
2. Barrow E, Hill J, Evans DG. Cancer risk in Lynch Syndrome. Fam Cancer. 2013; 12: 229-240.
3. National Comprehensive Cancer Network. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines. Colorectal Cancer Screening. Version
4. Fort Washington, PA: National Comprehensive Cancer Network; 2013.
5. Baglietto L, Lindor NM, Dowty JG, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst. 2010; 102: 193-201.
6. Bonadona V, Bonaiti B, Olschwang S, et al; French Cancer Genetics Network. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011; 305: 2304-2310.
7. Salovaara R, Loukola A, Kristo P, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2000; 18: 2193-2200.
8. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005; 352: 1851-1860.
9. Hampel H, Panescu J, Lockman J, et al. Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients. Cancer Res. 2007; 67: 9603.
10. Leenen CH, van Lier MG, van Doorn HC, et al. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer≤70 years. Gynecol Oncol. 2012; 125: 414-420.
11. Moline J, Mahdi H, Yang B, et al. Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center. Gynecol Oncol. 2013; 130: 121-126.
12. Egoavil C, Alenda C, Castillejo A, et al. Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers. PLoS One. 2013; 8: e79737.
13. Lu KH, Dinh M, Kohlmann W, et al. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol. 2005; 105: 569-574.
14. Ryan P, Mulligan AM, Aronson M, et al. Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. Cancer. 2012; 118: 681-688.
15. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006; 354: 261-269.
16. de Jong AE, Hendriks YM, Kleibeuker JH, et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology. 2006; 130: 665-671.
17. Jarvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000; 118: 829-834.
18. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004; 96: 261-268.
19. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999; 116: 1453-1456.
20. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009; 11: 35-41.
21. Vasen HF, Blanco I, Aktan-Collan K, et al; Mallorca group. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013; 62: 812-823.
22. Lancaster JM, Powell CB, Kauff ND, et al; Society of Gynecologic Oncologists Education Committee. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007; 107: 159-162.
23. Predictive Cancer Genetics Steering Committee. Ontario physicians' guide to referral of patients with family history of cancer to a familial cancer genetics clinic or genetics clinic. Ont Med Rev. 2001; 68: 24-30.
24. Lu FI, Gilks CB, Mulligan AM, et al. Prevalence of loss of expression of DNA mismatch repair proteins in primary epithelial ovarian tumors. Int J Gynecol Pathol. 2012; 31: 524-531.
25. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998; 58: 5248-5257.
26. Garg K, Leitao MM Jr, Kauff ND, et al. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol. 2009; 33: 925-933.
27. Shia J, Black D, Hummer AJ, Boyd J, Soslow RA. Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. Hum Pathol. 2008; 39: 116-125.
28. Buchanan DD, Tan YY, Walsh MD, et al. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. J Clin Oncol. 2014; 32: 90-100.
29. Kwon JS, Scott JL, Gilks CB, Daniels MS, Sun CC, Lu KH. Testing women with endometrial cancer to detect Lynch syndrome. J Clin Oncol. 2011; 29: 2247-2252.
30. Lu KH, Schorge JO, Rodabaugh KJ, et al. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol. 2007; 25: 5158-5164.
31. Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2006; 66: 7810-7817.
32. Carethers JM. Differentiating Lynch-like from Lynch syndrome. Gastroenterology. 2014; 146: 602-604.